We are international
Donate
TEXT SIZE   

Call the IMF Hotline. We are here for you. The IMF Office is open from 8:00AM - 5:00PM PST, Monday-Friday.

If you have a question, call the IMF InfoLine at (800) 452-CURE (800-452-2873) in the US and Canada. The InfoLine is open from 9:00 - 4:00 PT Monday - Friday. Elsewhere call (818) 487-7455. You can also contact us via the web.
IMF - Home Page
previous     next      view all

Frontline Therapy and MRD: Exciting New Data from France
Minimal residual disease (MRD) measurement through flow cytometry was shown to be a meaningful predictor in a frontline myeloma study published this month in the Journal of Clinical Oncology. In his blog, IMF Chairman Dr. Brian Durie explains that patients who achieved MRD-negative status remain in remission after a median follow-up of three years. This study “points the way to incorporation of MRD testing by flow cytometry into tailored approaches to achieve the very best results with therapy throughout the course of disease,” said Dr. Durie.

IMF Supports Support Group Leaders During 15th Annual Summit
Nearly 100 myeloma support group leaders gathered in Dallas, Texas over the weekend for the IMF's 15th Annual Support Group Leaders Summit. "During the year, these leaders give their all to their myeloma support groups," said Robin Tuohy, IMF Senior Director of Support Groups. "At the Summit, we give THEM as much as we can so they can share with their members the latest news about myeloma treatment, clinical trials, best practices for running a support group, and - perhaps most important of all - a chance to create lifelong bonds with fellow leaders across the nation." Leaders were instructed in the practice of tai chi (right) as a relaxation tool to pass along to their members.

Understanding Serum Free Light Chain and Serum Heavy/Light Chain Assays

The Understanding Serum Free Light Chain and Serum Heavy/Light Chain Assays booklet is devoted to two tests used in the diagnosis and monitoring of myeloma, the serum free light chain assay (Freelite®) and the serum heavy/light chain assay (Hevylite®).


IMF Unveils New Logo
Ushering in a new phase for the IMF and myeloma patients, the new logo reflects forward movement and hopefulness. This mirrors the significant progress being made in myeloma treatment, including the exceptional progress being made under the IMF’s signature Black Swan Research Initiative® to find a pathway to a cure for myeloma.

Freelite and Hevylite will help the Black Swan Research Initiative find the best treatment to cure multiple myeloma

Binding Site, a Birmingham, UK, based In-Vitro clinical diagnostic company, is pleased to announce that it has been chosen as an important diagnostic partner in the Black Swan ‘cure myeloma’ Research Initiative, sponsored by the International Myeloma Foundation (IMF).


Calling All Researchers: Submit Your Applications for IMF Grants
The IMF awards Brian D. Novis Junior and Senior Research Grants each year to "provide much-needed funding support for research projects being conducted by the best and the brightest in our field," according to IMF President Susie Novis. Funding grants since 1994 to honor IMF Co-Founder Brian D. Novis, the IMF is now the premier funder of myeloma research grants, having awarded over 115 grants that have opened the doors to new ideas and major advancements in treatments. Applications for 2015 grants are due by August 1st.

The IMF says Imnovid® (pomalidomide), the newest medication for advanced cases of multiple myeloma, is approved for reimbursement in Sweden, Spain, and Switzerland

Imnovid (pomalidomide), called Pomalyst in the US, was recently approved for reimbursement in Sweden, Spain, and Switzerland. Myeloma patients in these countries who have exhausted all other therapeutics will now have access to Imnovid through their government health programs. “Through our Black Swan Research Initiative®, the IMF is working to find a cure for myeloma,” said Susie Novis, "but in the meantime we are pleased to see that new innovative treatments are becoming available to more patients worldwide, and the IMF continues to fight for patients where access is not yet available." 


New IMF Publication: Vertebral Compression Fractures
A new IMF publication is available to help patients manage the painful and common problem of vertebral compression fractures (VCF), which can occur when bones in the spine are too weak to withstand the pressure placed upon them. The fractures can cause a number of painful issues.

Highlights from the 5th Annual IMWG Summit: Part 2
The IMF's International Myeloma Working Group (IMWG) held its 5th Annual Summit this year in Milan, Italy from June 9th-11th. Part 2 of IMF Medical Writer Debbie Birns’ comprehensive report on key developments from the Summit is now available HERE. It covers geriatric risk stratification; debates on frontline treatment options; new treatment approaches, such as virotherapy and immunotherapy with transgenic T-cells and chimeric antigen receptors; and new drugs in development.

GMA Summit Welcomes 30 Patient Advocates from 17 Regions
The IMF hosted the second annual Global Myeloma Alliance (GMA) Summit in Milan, Italy in June. The GMA, an advocacy initiative of the IMF that was established to mobilize the myeloma community to improve the lives of patients around the world, is a patient-driven alliance of organizations and individuals. Thirty members of the GMA from 17 regions attended the Summit, where they charted a course to foster further collaboration to achieve GMA’s goals.

previous     next      view all